Roger Schibli

This inventor holds 24 USPTO granted patents and 17 published patent applications, plus 7 CIPO patents and 13 EPO patents. Top assignees: Paul Scherrer Institut, Innate Pharma, Merck & Cie. Active years: 2002-2025.

USPTO Granted Patents = 24 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 7 (Patent Applications = 9)

EPO Patents = 13 (Patent Applications = 30)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 106(Granted Patents)

Location History:

Leibstadt, CH (2002)
Baden, CH (2006 - 2024)

Company Filing History:

14 out of 121

Paul Scherrer Institut

Itm Isotope Technologies Munich Se

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12208145 - [161 tb]-based radiopeptides (2025-01-28),

2. 12128110 - Transglutaminase conjugation method and linker (2024-10-29),

3. 12023390 - Isomerically pureF-labelled tetrahydrofolates (2024-07-02),

4. 11649268 - Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy (2023-05-16),

5. 11629201 - PSMA-binding agents and uses thereof (2023-04-18),

6. 11623014 - Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment (2023-04-11),

7. 11396649 - Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution (2022-07-26),

8. 10973936 - F-saccharide-folates (2021-04-13),

9. 10961246 - F-labelled folates as PET radiotracers (2021-03-30),

10. 10953114 - Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment (2021-03-23),

11. 10675359 - Enzymatic conjugation of antibodies (2020-06-09),

12. 10434180 - Enzymatic conjugation of polypeptides (2019-10-08),

13. 10357576 - 18F-labelled folate/antifolate analogues (2019-07-23),

14. 10322195 - [object Object] (2019-06-18),

15. 10132799 - Screening of conjugated antibodies (2018-11-20),

Title: Roger Schibli: Innovating in the Field of Radiopeptides

Introduction

Roger Schibli, a prominent inventor based in Baden, Switzerland, has made significant contributions to the field of biomedical engineering and radiopharmaceuticals. With an impressive portfolio of 24 patents, Schibli's work focuses primarily on innovative solutions for tumor treatment and antibody conjugation methods.

Latest Patents

Among his latest inventions, Schibli has developed a groundbreaking radiopeptide that comprises a radionuclide, specifically terbium-161, coordinated by a chelator. This radiopeptide is designed as a somatostatin receptor antagonist and offers potential therapeutic applications in treating tumor diseases. Additionally, he has pioneered a transglutaminase conjugation method that facilitates the creation of antibody-payload conjugates using microbial transglutaminase. This method involves conjugating a specially designed linker to a Gln residue in the heavy or light chain of an antibody, enhancing targeted drug delivery mechanisms.

Career Highlights

Throughout his career, Roger Schibli has held key positions in reputable organizations, including the Paul Scherrer Institute and Innate Pharma. His work at these institutions has not only been pivotal in advancing research but also in propelling innovative technologies from concept to application, thereby impacting patient care in oncology.

Collaborations

Schibli has collaborated with notable professionals in his field, including Rudolf Moser and Viola Groehn. These partnerships have fostered a robust research environment, encouraging the exchange of ideas and techniques that drive innovation in radiopeptide development and antibody technology.

Conclusion

Roger Schibli's innovative endeavors and contributions to the field of medicine underscore the importance of research and development in creating effective treatment solutions. His 24 patents reflect a commitment to advancing healthcare technologies, paving the way for future discoveries and improvements in cancer therapies.